---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Pathophysiology"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Pathophysiology. Topics: Pathophysiology, Bradykinin generation: activation of prekallikrein to plasma kallikrein, Role of C1 inhibitor in regulating the kallikrein-kinin system, Bradykinin and vascular permeability, and 8 further topics. 12 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/pathophysiology"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Pathophysiology

> “Hereditary angioedema (HAE) is characterized by C1 esterase inhibitor (C1INH) deficiency, leading to uninhibited kallikrein-kinin system (KKS) activation and bradykinin production resulting in angioedema attacks”

Source: [Intellia Therapeutics AAAAI poster (2026)](https://www.intelliatx.com/wp-content/uploads/AAAAI-2026_KKS-Modeling-Poster_with-Supplement.pdf)

<a id="topic-2.2.1.4-2"></a>

### Bradykinin generation: activation of prekallikrein to plasma kallikrein

> “In HAE-C1-INH, bradykinin is the primary mediator of swelling.”
> “This molecule arises from cleavage of high-molecular-weight kininogen by plasma kallikrein, which is activated from prekallikrein by factor XII.”
> “The resulting bradykinin nonapeptide increases vascular permeability and induces swelling (angioedema) through a specific receptor, B2”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.4-3"></a>

### Role of C1 inhibitor in regulating the kallikrein-kinin system

> “C1-INH is a serine protease inhibitor protein synthesized in hepatocytes that is crucial in regulating the plasma kallikrein–kinin system (KKS) and preventing excessive bradykinin production.”
> “HAE-C1-INH is caused by mutations in SERPING1, which encodes C1-INH, leading to reduced levels or impaired activity of C1-INH.”
> “This deficiency in turn leads to uncontrolled activation of the KKS and excessive bradykinin production, with bradykinin acting as the key mediator of the condition.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.4-4"></a>

### Bradykinin and vascular permeability

> “When the body does not have enough normal C1-INH protein, it ends up with excessive amounts of a protein fragment (peptide) called bradykinin.”
> “Bradykinin promotes inflammation by increasing the amount of fluid that leaks through the walls of blood vessels into body tissues (vascular permeability).”

Source: [MedlinePlus](https://www.medlineplus.gov/genetics/condition/hereditary-angioedema/)

<a id="topic-2.2.1.4-5"></a>

### Evidence for bradykinin as the mediator of attacks: plasma levels and the B2 receptor knockout model

> “In 1983, a pivotal study by Fields et al. implicated bradykinin as the likely primary mediator responsible for angioedema attacks.”
> “This hypothesis was further supported in 1999 by Nussberger et al, who analyzed plasma samples from individuals with HAE and reported elevated bradykinin levels in blood drawn from edematous sites compared to unaffected areas.”
> “Shortly thereafter, in 2002, a landmark experimental study using a double-knockout murine model deficient in both C1 inhibitor (C1-INH) and bradykinin B2 receptor (Bk2R) further confirmed the critical role of C1-INH deficiency and bradykinin in the pathogenesis of HAE.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.4-6"></a>

### Kinin receptors: bradykinin B1 and B2 receptors

> “Bradykinin (BK)-related peptides, the kinins, are released from kininogens by kallikreins and exert various physiological and pathological effects via 2 related G protein-coupled receptors (GPCRs) termed the bradykinin B1 and B2 receptors”
> “While kinins and their receptors mediate compensatory and protective vasodilator effects under various pathological conditions, they are also mediators of inflammation, producing plasma extravasation and edema and pain”

Source: [Lesage et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7316994/)

<a id="topic-2.2.1.4-7"></a>

### Bradykinin B2 receptor as the mediator of vascular permeability and swelling

> “which leads to the overproduction of bradykinin and activation of bradykinin B2 receptors.”
> “This increases vascular permeability and results in angioedema attacks.”
> “Bradykinin is rapidly metabolized by endogenous metalloproteases including angiotensin-converting enzyme (ACE).”
> “Increased vascular permeability and swelling induced by bradykinin are primarily mediated through the bradykinin B2 receptor.”
> “Bradykinin binds to and stimulates the bradykinin B2 receptor, thereby mediating vasodilatation and increased capillary permeability.”

Source: [Maurer et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9023902/)

<a id="topic-2.2.1.4-8"></a>

### Endothelial B2 receptor signaling: adherens junction disruption and resealing

> “Attacks are caused by overproduction of bradykinin, which binds to and activates vascular endothelial bradykinin B2 receptors, leading to disruption of the adherens junctions, resulting in increased vascular permeability and localised subcutaneous or submucosal swelling or both.”
> “The inhibition of signalling allows adherens junction resealing and progressive resolution of the accumulated interstitial fluid.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.1.4-9"></a>

### Bradykinin production pathways and blockade at the receptor

> “thus leaving the bradykinin B2 receptor functional to activation from bradykinin produced from kallikrein–kinin independent pathways.”
> “Conversely, bradykinin B2 receptor antagonists can directly block the receptor activity caused by bradykinin, regardless of its production pathway.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.2.1.4-10"></a>

### Kallikrein-kinin system targets of oral treatments

> “Currently approved and investigational oral treatments for HAE target components of the kallikrein‐kinin system, including plasma kallikrein (PKa), activated factor XII (FXIIa), or bradykinin B2 receptor (B2R; Figure 1).”
> “PKa inhibitors (e.g., berotralstat, sebetralstat, ATN249, VE‐4666, and VE‐4062) and FXIIa inhibitors prevent bradykinin generation by preventing cleavage of high molecular weight kininogen, whereas B2R antagonists (e.g., deucrictibant) block bradykinin binding.”

Source: [Valerieva et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11431061/)

<a id="topic-2.2.1.4-11"></a>

### Mediators of swelling in HAE with normal C1-INH

> “Current evidence indicates that excessive bradykinin generation is still involved in most cases (HAE-FXII, HAE-PLG, HAE-KNG, HAE-HSST, and HAE-CPN).”
> “However, other mediators such as VEGF and angiopoietin have emerged as candidate contributors, potentially increasing vascular permeability either directly (HAE-MYOF, HAE-DAB2IP) or indirectly (HAE-ANGPT).”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.1.4-12"></a>

### Company statement: bradykinin B2 receptor activation in angioedema

> “Bradykinin is the principal mediator of the signs and symptoms that represent AE-BK attacks, acting as a potent and selective agonist of the bradykinin B2 receptor.”
> “Excessive bradykinin generation, as in HAE, promotes vascular permeability by activating the bradykinin B2 receptor in vascular endothelium cells, leading to plasma extravasation and subcutaneous or submucosal tissue swelling typical of an angioedema attack.”
> “Bradykinin B2 receptor inhibition is a clinically validated mechanism for the treatment of HAE, as demonstrated by icatibant, which is a peptide bradykinin B2 receptor antagonist approved in Europe in 2008 and in the United States in 2011 (as FIRAZYR).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
